Oral chemotherapy has evolved with several new agents such as capecitabine and UFT in active clinical trials or already approved for use in the western world. Several distinct issues, apart from the usual criteria for selecting patients for intravenous chemotherapy, dictate patient selection for these drugs. This article discusses these issues, which include patient preference, selection, and compliance.